AIA Group Ltd Has $29.09 Million Position in Danaher Corporation (NYSE:DHR)

AIA Group Ltd trimmed its position in Danaher Corporation (NYSE:DHR) by 16.6% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 141,923 shares of the conglomerate’s stock after selling 28,147 shares during the period. Danaher makes up 0.7% of AIA Group Ltd’s portfolio, making the stock its 28th biggest holding. AIA Group Ltd’s holdings in Danaher were worth $29,094,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Nuveen LLC acquired a new stake in shares of Danaher during the 1st quarter worth $833,941,000. GAMMA Investing LLC boosted its stake in shares of Danaher by 24,958.2% during the first quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate’s stock valued at $383,524,000 after purchasing an additional 1,863,381 shares in the last quarter. Two Sigma Advisers LP boosted its stake in shares of Danaher by 4,248.8% during the fourth quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate’s stock valued at $376,347,000 after purchasing an additional 1,601,800 shares in the last quarter. Capital World Investors boosted its stake in shares of Danaher by 32.7% during the fourth quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate’s stock valued at $1,460,215,000 after purchasing an additional 1,566,658 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in shares of Danaher by 44.5% during the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after purchasing an additional 1,450,703 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Price Performance

DHR stock opened at $200.70 on Monday. The stock has a market cap of $143.71 billion, a PE ratio of 42.70, a P/E/G ratio of 2.80 and a beta of 0.73. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. Danaher Corporation has a one year low of $171.00 and a one year high of $279.90. The firm has a 50 day simple moving average of $198.46 and a two-hundred day simple moving average of $200.62.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating analysts’ consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%. The company had revenue of $5.94 billion for the quarter, compared to analysts’ expectations of $5.83 billion. During the same period last year, the firm posted $1.72 EPS. Danaher’s revenue for the quarter was up 3.4% compared to the same quarter last year. On average, analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on DHR shares. Argus cut their price objective on Danaher from $260.00 to $240.00 in a research note on Wednesday, April 23rd. Evercore ISI decreased their price objective on Danaher from $230.00 to $226.00 and set an “outperform” rating for the company in a report on Tuesday, July 8th. The Goldman Sachs Group decreased their price objective on Danaher from $260.00 to $240.00 and set a “neutral” rating for the company in a report on Wednesday, April 23rd. Royal Bank Of Canada reiterated an “outperform” rating and set a $250.00 price target on shares of Danaher in a report on Wednesday, April 23rd. Finally, Scotiabank upgraded Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 price objective for the company in a research note on Friday, July 11th. Three research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and an average target price of $247.61.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.